Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Advances in Neurology|December 31, 2005
Dementia in Parkinson's diseaseGregory A Rippon, Karen S MarderSleep & Breathing = Schlaf & Atmung|September 18, 2007
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apneaThomas Roth, Gregory A Rippon, Sanjay AroraSexual Medicine Reviews|March 26, 2017
Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord InjuryDana A Ohl, Martin Carlsson, Vera J Stecher, et al.Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2005
Corticobasal syndrome with novel argyrophilic glial inclusionsGregory A Rippon, S M Staugaitis, Steven S M Chin, et al.Journal of Occupational and Environmental Medicine|February 6, 2010
Impaired health status, daily functioning, and work productivity in adults with excessive sleepinessBonnie Dean, Daniel Aguilar, Colin Shapiro, et al.The Journal of Clinical Psychiatry|January 7, 2010
A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depressionAndrew D Krystal, John R Harsh, Ronghua Yang, et al.Archives of Neurology|June 18, 2003
Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementiaGregory A Rippon, Richard Crook, Matthew Baker, et al.Archives of Neurology|March 15, 2006
An observational study of cognitive impairment in amyotrophic lateral sclerosisGregory A Rippon, Nikolaos Scarmeas, Paul H Gordon, et al.Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.Pageof 2